Felicitex Therapeutics | Press Release

top of page

"Developing novel treatments for Dormant Cancers - targeting resistance, metastasis, and relapse."

July 20, 2015

Emerging Company Profile - BioCentury on BioBusiness

June 24, 2015

Massachusetts Grant Provides $200,000 Non-dilutive Funding to Felicitex Therapeutics

May 19, 2015

Felicitex Therapeutics and Diaxonhit Announce Global Exclusive License of a Series of Lead-stage Anti-cancer Compounds from Diaxonhit for the Development of Therapeutics against Quiescent Cancer Cells

November 7, 2014

Felicitex Therapeutics and Selvita Initiate Strategic Collaboration to Target Cancer Quiescence

© 2019 by Felicitex Therapeutics, Inc »« 27 Strathmore Road Natick, MA 01760 1-919-213-0025 (p) Click here to Contact Us!

Felicitex Therapeutics Inc.

27 Strathmore Rd.

Natick, MA 01760

(919) 213-0025

info@felicitex.com

bottom of page